Growth from birth to adulthood in a patient with the neonatal form of Bartter syndrome.
Growth from birth to the age of 19 years was studied in a patient with the neonatal form of Bartter syndrome. The initial modes of therapy (extra fluid, potassium supplements and triamterene) resulted in satisfactory but not optimal growth. Treatment with spironolactone together with potassium led to impressive catch-up growth. When the patient reached the age of 9 years, indomethacin therapy was started, which resulted in a second growth acceleration and was also accompanied by a significant reduction of both polyuria and hypercalciuria. Puberty developed normally, menarche occurred at 12 years 4 months and a normal adult height of 162 cm was reached at the age of 14 years. Treatment with prostaglandin synthetase inhibitors seems to be the best therapy for children with the neonatal form of Bartter syndrome.
Proesmans
W
W
Department of Paediatrics, University Hospital Gasthuisberg, Leuven, Belgium.
Massa
G
G
Vanderschueren-Lodeweyckx
M
M
D000293:Adolescent; D000328:Adult; D001477:Bartter Syndrome / Q000151:congenital* / Q000188:drug therapy / Q000503:physiopathology; D002118:Calcium / Q000652:urine; D002648:Child; D002675:Child, Preschool; D004231:Diuresis / Q000187:drug effects; D004573:Electrolytes / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006128:Growth / Q000187:drug effects; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D011188:Potassium / Q000627:therapeutic use; D011627:Puberty; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use
D004573:Electrolytes; D013148:Spironolactone; D011188:Potassium; D002118:Calcium; D007213:Indomethacin